Imatinib mesilate: new perspectives in the treatment of solid tumours

Author： Smirne Carlo Carbone Anna Pirisi Mario Bellone Graziella

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.16, Iss.10, 2006-10, pp. : 1359-1370

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib mesilate for the treatment of gastrointestinal stromal tumour

By Cassier Philippe A Dufresne Armelle Arifi Samia Sayadi Hiba El Labidi Intidar Ray-Coquard Isabelle Tabone Séverine Méeus Pierre Ranchère Dominique Sunyach Marie-Pierre Decouvelaere Anne-Valérie Alberti Laurent Blay Jean-Yves

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 7, 2008-05 ,pp. : 1211-1222

Informa Healthcare

Access to resources Recommend Favorite

Imatinib Mesylate: In the Treatment of Gastrointestinal Stromal Tumours

By Croom K.F. Perry C.M.

Drugs, Vol. 63, Iss. 5, 2003-01 ,pp. : 513-522

Adis International

Access to resources Recommend Favorite

Treatment of gastrointestinal stromal tumours: imatinib, sunitinib – and then?

By Nilsson Bengt Nilsson Ola Ahlman Håkan

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 457-468

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours

By Huse Daniel M.

Clinical Drug Investigation, Vol. 27, Iss. 2, 2007-01 ,pp. : 85-93

Adis International

Access to resources Recommend Favorite

Choi criteria are superior to Response Evaluation Criteria in Solid Tumours (RECIST) for evaluating GI stromal tumours in imatinib-treated patients

Inpharma, Vol. 1, Iss. 1588, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite